Pharmaxis Ltd (AU:SNT) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Syntara Limited, formerly known as Pharmaxis, has undergone a significant transformation to focus on innovative healthcare solutions, reducing their team and expenses to concentrate on promising drug candidates like SNT-5505. The company achieved full recruitment for its phase 2 trial in myelofibrosis and secured non-dilutive funding for myelodysplastic syndrome studies, reinforcing the value of its lead asset. With upcoming data presentations and FDA engagements, Syntara is poised for further advancements in its hematology program.
For further insights into AU:SNT stock, check out TipRanks’ Stock Analysis page.
Trending Articles
- What If Elon Musk Actually Did Buy the Comcast (NASDAQ:CMCSA) Channels?
- Long John Silver: Pirate, Mutineer, and Personal Finance Guru?
- ETH, ETHQ, ETHX: 3 Ethereum ETFs to Boost Portfolio Returns
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
